Pasithea Therapeutics (KTTA) Total Non-Current Liabilities (2021 - 2026)
Pasithea Therapeutics recorded quarterly Total Non-Current Liabilities of $52966.0 in Q1 2026, up 13.0% quarter-over-quarter from $46871.0 in Q4 2025, and down 37.91% year-over-year from $85305.0 in Q1 2025.
Pasithea Therapeutics' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $52966.0 for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 37.91% year-over-year to $52966.0; the TTM figure through Mar 2026 stood at $52966.0 (down 37.91% YoY), while the FY2025 annual figure was $46871.0, down 71.1% from the prior year.
- Total Non-Current Liabilities came in at $52966.0 for Q1 2026 at Pasithea Therapeutics, up from $46871.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.3 million in Q3 2022 to a low of $46871.0 in Q3 2025.
- A 5-year average of $330923.6 and a median of $162172.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities soared 147.21% in 2022 and tumbled 92.68% in 2024, its largest moves.
- Pasithea Therapeutics' Total Non-Current Liabilities stood at $804207.0 in 2022, then sank by 89.51% to $84366.0 in 2023, then jumped by 92.22% to $162172.0 in 2024, then tumbled by 71.1% to $46871.0 in 2025, then increased by 13.0% to $52966.0 in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $52966.0, $46871.0, and $46871.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | 52,966.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52,966.00 |
| Dec 31, 2025 | 46,871.00 |
| Sep 30, 2025 | 46,871.00 |
| Jun 30, 2025 | 93,741.00 |
| Mar 31, 2025 | 85,305.00 |
| Dec 31, 2024 | 162,172.00 |
| Sep 30, 2024 | 163,578.00 |
| Jun 30, 2024 | 93,272.00 |
| Mar 31, 2024 | 57,650.00 |
| Dec 31, 2023 | 84,366.00 |
| Sep 30, 2023 | 239,876.00 |
| Jun 30, 2023 | 330,139.00 |
| Mar 31, 2023 | 787,630.00 |
| Dec 31, 2022 | 804,207.00 |
| Sep 30, 2022 | 1.31 Mn |
| Jun 30, 2022 | 604,048.00 |
| Mar 31, 2022 | 667,503.00 |
| Dec 31, 2021 | 1.45 Mn |
| Sep 30, 2021 | 528,096.00 |